NCT05216601 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19 | Biotech Hunter

Enrollment

107

Participants

Timeline

Start Date

May 6, 2022

Primary Completion Date

July 26, 2022

Study Completion Date

November 30, 2022

Conditions

COVID-19 Vaccine

Interventions

BIOLOGICAL

MVC-COV1901

Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region. Group A and B

BIOLOGICAL

MVC-COV1901(Beta)-15

Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-15 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region

BIOLOGICAL

MVC-COV1901(Beta)-25

Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-25 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region

Trial Locations (2)

Unknown

Taipei Medical University Hospital, Taipei

Tri-Service General Hospital, Taipei